Schering-Plough Announces FDA Approval of Saphris (asenapine)
Links shared publicly online about this topic.
- 1,822total visits
Schering-Plough Announces FDA Approval of Saphris (asenapine)
View full resource at drugs.com
Tags: Schizophrenia, Psychotic Disorder, Disease and Condition, FDA
Most Recently Shared on August 15, 2009 at 6:07 am By:
Schering-Plough Announces FDA Approval of Saphris (asenapine) - http://bit.ly/XvAmd
Saphris: It's Different without Actually Being Different | Psydir News
news.psydir.com — “On August 14th, the FDA approved Schering-Plough's second generation antipsychotic drug Saphris (asenapine) for the acute treatment of schizophrenia, and the acute treatment of mania/mixed episodes associated with bipolar I disorder (1). Question: Should I, at all be concerned that there are more actual published peer-reviewed articles of this drug being tested in rats (2, 3, 4, 5, 6 ) than in hum...” View full resource at news.psydir.com
Most Recently Shared on September 4, 2009 at 11:34 am By:
Saphris: It's Different without Actually Being Different http://ow.ly/15NICd
FDA OKs Schering-Plough Drug for Schizophrenia, Bipolar - WSJ.com
online.wsj.com — “The FDA gave final approval to Schering-Plough's Saphris, a treatment for both schizophrenia and bipolar disorder in adults.” View full resource at online.wsj.com
Most Recently Shared on August 19, 2009 at 7:15 pm By:
FDA Approves Asenapine for Schizophrenia, Bipolar Disorder: http://bit.ly/4uyHBi
Saphris approved for schizophrenia and bipolar I disorder - MPR
empr.com — “The FDA has approved Saphris (asenapine sublingual tablets, from Schering-Plough), a psychotropic agent, for the acute treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.” View full resource at empr.com
Most Recently Shared on August 14, 2009 at 3:41 pm By:
MPR News: Saphris approved for schizophrenia and bipolar I disorder: The FDA has approved Saphris (asen.. http://bit.ly/A4RkP
Advertisement

